161 filings
Page 5 of 9
8-K
l4b0n28nehf7x8ma7dhv
20 Dec 18
Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
12:00am
8-K
4u0be 1no9saw9o823b6
3 Dec 18
Departure of Directors or Certain Officers
5:26pm
8-K
jfyd4u
9 Nov 18
Eiger Bio Reports Third Quarter 2018 Financial Results
4:01pm
8-K
itkrimvo e2
9 Nov 18
Regulation FD Disclosure
12:00am
8-K
tf690y ogco5u
23 Oct 18
Results of Operations and Financial Condition
5:21pm
8-K
chs6 usph
22 Oct 18
Other Events
4:03pm
8-K
uyqjji0f0hpkvjked8
16 Aug 18
Entry into a Material Definitive Agreement
4:18pm
8-K
y1064 3wb
13 Aug 18
Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results
4:48pm
8-K
faes0oknmbic
15 Jun 18
Submission of Matters to a Vote of Security Holders
12:00am
8-K
8haus3yuemzej515s06
25 May 18
Other Events
4:43pm
8-K
ubayui6
23 May 18
Other Events
4:00pm
8-K
m4ngs6c623
16 May 18
Entry into a Material Definitive Agreement
8:16am
8-K
c2ubvn11q
11 May 18
Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results
5:21pm
8-K
qafp a0rgqr8il
16 Mar 18
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
12:00am
8-K
995js ciu2
22 Feb 18
Regulation FD Disclosure
12:00am
8-K
bunh8wobd8kt6
18 Jan 18
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
12:00am
8-K
gm2vs8 spyol
8 Jan 18
Entry into a Material Definitive Agreement
12:00am
8-K
scmlrfnu0kj48s
9 Nov 17
Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results
12:00am
8-K
h8bww n5dz6yj5
30 Oct 17
Results of Operations and Financial Condition
12:00am
8-K
v0zbn13n8mxy yz4se1p
23 Oct 17
Other Events
12:00am